Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: Results from a prospective institutional database

Endocrine-Related Cancer

Volumn 20, Issue 2, 2013, Pages 187-196

  Ter Minassian, Monica ^a,b   Chan, Jennifer A ^a   Hooshmand, Susanne M ^a   Brais, Lauren K ^a   Daskalova, Anastassia ^a   Heafield, Rachel ^a   Buchanan, Laurie ^a   Qian, Zhi Rong ^a   Fuchs, Charles S ^a   Lin, Xihong ^b   Christiani, David C ^b   Kulke, Matthew H ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Chromogranin A; Disease free survival; Neuroendocrine tumors; Overall survival

Indexed keywords

ALKALINE PHOSPHATASE; CHROMOGRANIN A;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL FEATURE; DATA BASE; DIARRHEA; DISEASE DURATION; DISEASE FREE SURVIVAL; FEMALE; FLUSHING; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GASTROINTESTINAL TUMOR; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUROENDOCRINE TUMOR; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PROSPECTIVE STUDY; SMALL INTESTINE TUMOR; SURVIVAL TIME; TUMOR DIAGNOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHROMOGRANIN A; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PROGNOSIS; RECURRENCE; YOUNG ADULT;

EID: 84876777892     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0340     Document Type: Article

References (43)

1. Arnold R, Wilke A, Rinke A, Mayer C, Kann PH, Klose KJ, Scherag A, Hahmann M, Muller HH & Barth P 2008 Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clinical Gastroenterology and Hepatology 6 820-827. (doi:10.1016/j.cgh.2008.02. 052)
2. Boninsegna L, Panzuto F, Partelli S, Capelli P, Delle Fave G, Bettini R, Pederzoli P, Scarpa A & Falconi M 2012 Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. European Journal of Cancer 48 1608-1615. (doi:10.1016/j.ejca.2011. 10.030)
3. Boudreaux JP, Klimstra DS, Hassan MM, Woltering EA, Jensen RT, Goldsmith SJ, Nutting C, Bushnell DL, Caplin ME & Yao JC 2010 The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas 39 753-766. (doi:10.1097/MPA.0b013e3181ebb2a5)
4. Cain KC, Harlow SD, Little RJ, Nan B, Yosef M, Taffe JR & Elliott MR 2011 Bias due to left truncation and left censoring in longitudinal studies of developmental and disease processes. American Journal of Epidemiology 173 1078-1084. (doi:10.1093/aje/kwq481)
5. Casadei R, Ricci C, Pezzilli R, Campana D, Tomassetti P, Calculli L, Santini D, D'Ambra M & Minni F 2010 Are there prognostic factors related to recurrence in pancreatic endocrine tumorsPancreatology 10 33-38. (doi:10.1159/000217604)
6. Clancy TE, Sengupta TP, Paulus J, Ahmed F, Duh MS & Kulke MH 2006 Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors. Digestive Diseases and Sciences 51 877-884. (doi:10.1007/s10620-006-9345-4)
7. Ekeblad S, Skogseid B, Dunder K, Oberg K & Eriksson B 2008 Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clinical Cancer Research 14 7798-7803. (doi:10.1158/1078-0432.CCR-08-0734)
8. Faggiano A, Ferolla P, Grimaldi F, Campana D, Manzoni M, Davi MV, Bianchi A, Valcavi R, Papini E, Giuffrida D et al. 2012 Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian Epidemiological study: THE NET MANAGEMENT STUDY. Journal of Endocrinological Investigation 35 817-823. (doi:10.3275/8102)
9. Gomez-Rivera F, Stewart AE, Arnoletti JP, Vickers S, Bland KI & Heslin MJ 2007 Surgical treatment of pancreatic endocrine neoplasms. American Journal of Surgery 193 460-465. (doi:10.1016/j.amjsurg.2006.10.016)
10. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H et al. 2009 SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975-2009-pops09/, based on November 2011 SEER data submission, posted to the SEER web site, April 2012.
11. Jann H, Roll S, Couvelard A, Hentic O, Pavel M, Muller-Nordhorn J, Koch M, Rocken C, Rindi G, Ruszniewski P et al. 2011 Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer 117 3332-3341. (doi:10.1002/cncr.25855)
12. Janson ET, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E & Oberg K 1997 Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Annals of Oncology 8 685-690. (doi:10.1023/A:1008215730767)
13. Kimura W, Tezuka K & Hirai I 2011 Surgical management of pancreatic neuroendocrine tumors. Surgery Today 41 1332-1343. (doi:10.1007/s00595-011-4547- 6)
14. Klimstra DS, Modlin IR, Coppola D, Lloyd RV & Suster S 2010 The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 39 707-712. (doi:10.1097/MPA. 0b013e3181ec124e)
15. Kolby L, Bernhardt P, Sward C, Johanson V, Ahlman H, Forssell-Aronsson E, Stridsberg M, Wangberg B & Nilsson O 2004 Chromogranin A as a determinant of midgut carcinoid tumour volume. Regulatory Peptides 120 269-273. (doi:10.1016/j.regpep.2004.03.017)
16. Korse CM, Taal BG, de Groot CA, Bakker RH & Bonfrer JM 2009 Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor. Journal of Clinical Oncology 27 4293-4299. (doi:10.1200/JCO.2008.18.7047)
17. Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, Marx SJ, Pasieka JL, Pommier RF, Yao JC et al. 2010 NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 39 735-752. (doi:10.1097/MPA.0b013e3181ebb168)
18. Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ et al. 2011 Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. Journal of Clinical Oncology 29 934-943. (doi:10.1200/JCO.2010.33.2056)
19. Kwekkeboom DJ, de Herder WW & Krenning EP 2011 Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Endocrinology and Metabolism Clinics of North America 40 173-185. (doi:10.1016/j.ecl.2010.12.003)
20. Landerholm K, Zar N, Andersson RE, Falkmer SE & Jarhult J 2011 Survival and prognostic factors in patients with small bowel carcinoid tumour. British Journal of Surgery 98 1617-1624. (doi:10.1002/bjs.7649)
21. Lawrence B, Gustafsson BI, Kidd M, Pavel M, Svejda B & Modlin IM 2011a The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinology and Metabolism Clinics of North America 40 111-134. (doi:10.1016/j.ecl. 2010.12.001)
22. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M & Modlin IM 2011b The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinology and Metabolism Clinics of North America 40 1-18. (doi:10.1016/j.ecl.2010.12. 005)
23. Le Roux C, Lombard-Bohas C, Delmas C, Dominguez-Tinajero S, Ruszniewski P, Samalin E, Raoul JL, Renard P, Baudin E, RobaskiewiczM et al. 2011 Relapse factors for ileal neuroendocrine tumours after curative surgery: a retrospective French multicentre study. Digestive and Liver Disease 43 828-833. (doi:10.1016/j.dld.2011.04.021)
24. Maggard MA, O'Connell JB & Ko CY 2004 Updated population-based review of carcinoid tumors. Annals of Surgery 240 117-122. (doi:10.1097/01.sla. 0000129342.67174.67)
25. Modlin IM, Moss SF, Chung DC, Jensen RT & Snyderwine E 2008 Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. Journal of the National Cancer Institute 100 1282-1289. (doi:10.1093/jnci/djn275)
26. Nehar D, Lombard-Bohas C, Olivieri S, Claustrat B, Chayvialle JA, Penes MC, Sassolas G & Borson-Chazot F 2004 Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. Clinical Endocrinology 60 644-652. (doi:10.1111/j.1365-2265.2004.02030.x)
27. Nikou GC, Marinou K, Thomakos P, Papageorgiou D, Sanzanidis V, Nikolaou P, Kosmidis C, Moulakakis A & Mallas E 2008 Chromogranin a levels in diagnosis, treatment and follow-up of 42 patients with non-functioning pancreatic endocrine tumours. Pancreatology 8 510-519. (doi:10.1159/000152000)
28. Pape UF, Berndt U, Muller-Nordhorn J, Bohmig M, Roll S, Koch M, Willich SN & Wiedenmann B 2008a Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocrine-Related Cancer 15 1083-1097. (doi:10.1677/ERC-08-0017)
29. Pape UF, Jann H, Muller-Nordhorn J, Bockelbrink A, Berndt U, Willich SN, Koch M, Rocken C, Rindi G & Wiedenmann B 2008b Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 113 256-265. (doi:10.1002/cncr.23549)
30. Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P et al. 2006 TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Archiv 449 395-401. (doi:10.1007/s00428-006-0250-1)
31. Rindi G, Arnold R, Bosman FT, Capella C, Klimstra DS, Kloppel G, Komminoth P & Solcia E 2010 Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In World Health Organization Classification of Tumours, 4th edn, pp 13-14. Eds FT Bosman, F Carniero, RH Hruban & ND Theise. Lyon: International Agency for Research on Cancer Press.
32. Shariff SZ, Cuerden MS, Jain AK & Garg AX 2008 The secret of immortal time bias in epidemiologic studies. Journal of the American Society of Nephrology 19 841-843. (doi:10.1681/ASN.2007121354)
33. Solcia E, Rindi G, Larosa S & Capella C 2000 Morphological, molecular, and prognostic aspects of gastric endocrine tumors. Microscopic Research and Technique 48 339-348. (doi:10.1002/(SICI)1097-0029(20000315)48:6! 339::AID-JEMT4O3.0.CO;2-D)
34. Stivanello M, Berruti A, Torta M, Termine A, Tampellini M, Gorzegno G, Angeli A & Dogliotti L 2001 Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience. Annals of Oncology 12 (Suppl 2) S73-S77. (doi:10.1093/annonc/12.suppl-2.S73)
35. Strosberg JR, Nasir A, Hodul P & Kvols L 2008 Biology and treatment of metastatic gastrointestinal neuroendocrine tumors. Gastrointestinal Cancer Research 2 113-125.
36. Strosberg JR, Cheema A,Weber J, Han G, Coppola D & Kvols LK 2011 Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. Journal of Clinical Oncology 29 3044-3049. (doi:10.1200/JCO.2011.35.1817)
37. Strosberg JR, Cheema A, Weber JM, Ghayouri M, Han G, Hodul PJ & Kvols LK 2012 Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Annals of Surgery 256 321-325. (doi:10.1097/SLA. 0b013e31824e6108)
38. Vinik AI, Silva MP, Woltering EA, Go VL, Warner R & Caplin M 2009 Biochemical testing for neuroendocrine tumors. Pancreas 38 876-889. (doi:10.1097/MPA.0b013e3181bc0e77)
39. Vinik AI, Woltering EA, Warner RR, Caplin M, O'Dorisio TM, Wiseman GA, Coppola D & Go VL 2010 NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas 39 713-734. (doi:10.1097/MPA.0b013e3181ebaffd)
40. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A et al. 2008 One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. Journal of Clinical Oncology 26 3063-3072. (doi:10.1200/JCO.2007.15.4377)
41. Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen S, St Peter J, Cherfi A & Oberg KE 2011 Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. Journal of Clinical Endocrinology and Metabolism 96 3741-3749. (doi:10.1210/jc.2011-0666)
42. Yao JC, Hainsworth JD, Wolin EM, Pavel ME, Baudin E, Gross D, Ruszniewski P, Tomassetti P, Panneerselvam A, Saletan S et al. 2012 Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (ECO) or placebo (PCO) among patients with advanced neuroendocrine tumors (NET). Journal of Clinical Oncology 30 abstr 157.
43. Zerbi A, Falconi M, Rindi G, Delle Fave G, Tomassetti P, Pasquali C, Capitanio V, Boninsegna L & Di Carlo V 2010 Clinicopathological features of pancreatic endocrine tumors: a prospective multicenter study in Italy of 297 sporadic cases. American Journal of Gastroenterology 105 1421-1429. (doi:10.1038/ajg.2009.747)